Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment

Vaccine

Volumn 34, Issue 51, 2016, Pages 6597-6609

  Clarke, David K ^a   Hendry, R Michael ^b   Singh, Vidisha ^b   Rose, John K ^c   Seligman, Stephen J ^d,e   Klug, Bettina ^f   Kochhar, Sonali ^g   Mac, Lisa Marie ^b   Carbery, Baevin ^b   Chen, Robert T ^b  

^a Profectus BioSciences Inc   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

^f PAUL EHRLICH INSTITUT   (Germany)

^g Healthcare Management Consultants   (India)

Author keywords

Brighton collaboration; Risk benefit assessment; Vaccine safety; Vaccines; Vesicular stomatitis virus vector; Viral vector

Indexed keywords

GAG PROTEIN; LIVE VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS VACCINE; VESICULAR STOMATITIS VIRUS VECTOR; VIRUS VACCINE; VIRUS VECTOR; DRUG CARRIER; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ARTICLE; BLOOD; CELLULAR IMMUNITY; CLINICAL EVALUATION; DRUG EFFICACY; DRUG SAFETY; EXPRESSION VECTOR; GENE EXPRESSION; HETEROLOGOUS IMMUNITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SALIVA; SEROPREVALENCE; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; URINE; VACCINATION; VACCINE PRODUCTION; VESICULOVIRUS; VIRUS ATTENUATION; VIRUS ENVELOPE; VIRUS IMMUNITY; VIRUS RECOMBINANT; VIRUS VIRULENCE; WILD TYPE; ADVERSE DRUG REACTION; ANIMAL; GENE VECTOR; GENETICS; IMMUNOLOGY; PATHOLOGY; PRECLINICAL STUDY; PRIMATE; RISK ASSESSMENT;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HUMANS; PRIMATES; RISK ASSESSMENT; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VESICULOVIRUS;

EID: 84979657086     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.06.071     Document Type: Article

References (93)

1. [1] Liniger, M., Zuniga, A., Naim, H.Y., Use of viral vectors for the development of vaccines. Expert Rev Vacc 6 (2007), 255–266.
2. [2] Excler, J.L., Parks, C.L., Ackland, J., Rees, H., Gust, I.D., Koff, W.C., Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals: J Int Assoc Biol Stand 38 (2010), 511–521.
3. [3] Limbach, K.J., Richie, T.L., Viral vectors in malaria vaccine development. Parasite Immunol 31 (2009), 501–519.
4. [4] Xing, Z., Lichty, B.D., Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis 86 (2006), 211–217.
5. [5] Naim, H.Y., Applications and challenges of multivalent recombinant vaccines. Human Vacc Immunother, 9, 2012.
6. [6] Johnson, J.A., Barouch, D.H., Baden, L.R., Nonreplicating vectors in HIV vaccines. Curr Opin HIV AIDS 8 (2013), 412–420.
7. [7] Parks, C.L., Picker, L.J., King, C.R., Development of replication-competent viral vectors for HIV vaccine delivery. Curr Opin HIV AIDS 8 (2013), 402–411.
8. [8] Wong, G., Audet, J., Fernando, L., Fausther-Bovendo, H., Alimonti, J.B., Kobinger, G.P., et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine, 2014.
9. [9] Mullard, A., Experimental Ebola drugs enter the limelight. Lancet, 384, 2014, 649.
10. [10] Henao-Restrepo, A.M., Longini, I.M., Egger, M., Dean, N.E., Edmunds, W.J., Camacho, A., et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386 (2015), 857–866.
11. [11] WHO Initiative for Vaccine Research. WHO informal consultation on characterization and quality aspect of vaccines based on live viral vectors. December 2003.
12. [12] Amarasinghe, A., Black, S., Bonhoeffer, J., Carvalho, S.M., Dodoo, A., Eskola, J., et al. Effective vaccine safety systems in all countries: a challenge for more equitable access to immunization. Vaccine 31:Suppl 2 (2013), B108–B114.
13. [13] MacDonald, N.E., Smith, J., Appleton, M., Risk perception, risk management and safety assessment: what can governments do to increase public confidence in their vaccine system?. Biologicals: J Int Assoc Biol Stand 40 (2012), 384–388.
14. [14] Chen, R.T., Hibbs, B., Vaccine safety: current and future challenges. Pediatr Ann 27 (1998), 445–455.
15. [15] Kohl, K.S., Bonhoeffer, J., Chen, R., Duclos, P., Heijbel, H., Heininger, U., et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf 12 (2003), 335–340.
16. [16] Monath, T.P., Seligman, S.J., Robertson, J.S., Guy, B., Hayes, E.B., Condit, R.C., et al. Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine 33 (2015), 62–72.
17. [17] John, K., Rose, D.K.C., Rhabdoviruses as vaccine vectors: from initial development to clinical trials Biology and pathogenesis of rhabdo- and filoviruses, 2015, World Scientific, New Jersey p. 199–22.
18. [18] Fuchs, J.D., Frank, I., Elizaga, M.L., Allen, M., Frahm, N., Kochar, N., et al. First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090). Open Forum Infect Dis, 2, 2015, ofv082.
19. [19] Martinez, I., Rodriguez, L.L., Jimenez, C., Pauszek, S.J., Wertz, G.W., Vesicular stomatitis virus glycoprotein is a determinant of pathogenesis in swine, a natural host. J Virol 77 (2003), 8039–8047.
20. [20] Feldmann, H., Jones, S.M., Daddario-DiCaprio, K.M., Geisbert, J.B., Stroher, U., Grolla, A., et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog, 3, 2007, e2.
21. [21] Publicover, J., Ramsburg, E., Rose, J.K., Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol 78 (2004), 9317–9324.
22. [22] Fields, B.N., Hawkins, K., Human infection with the virus of vesicular stomatitis during an epizootic. New Engl J Med 277 (1967), 989–994.
23. [23] Johnson, K.M., Vogel, J.E., Peralta, P.H., Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hygiene 15 (1966), 244–246.
24. [24] Cline, B.L., Ecological associations of vesicular stomatitis virus in rural Central America and Panama. Am J Trop Med Hygiene 25 (1976), 875–883.
25. [25] Tesh, R.B., Peralta, P.H., Johnson, K.M., Ecologic studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an area of endemic VSV activity. Am J Epidemiol 90 (1969), 255–261.
26. [26] Hanson RP, Karstad L. Further studies on enzootic vesicular stomatitis. In: Proc US Livestock Sanit Assoc; 1957.
27. [27] Iverson, L.E., Rose, J.K., Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 23 (1981), 477–484.
28. [28] Wertz, G.W., Perepelitsa, V.P., Ball, L.A., Gene rearrangement attenuates expression and lethality of a nonsegmented negative strand RNA virus. Proc Natl Acad Sci USA 95 (1998), 3501–3506.
29. [29] Ball, L.A., Pringle, C.R., Flanagan, B., Perepelitsa, V.P., Wertz, G.W., Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol 73 (1999), 4705–4712.
30. [30] Flanagan, E.B., Zamparo, J.M., Ball, L.A., Rodriguez, L.L., Wertz, G.W., Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J Virol 75 (2001), 6107–6114.
31. [31] Schnell, M.J., Buonocore, L., Whitt, M.A., Rose, J.K., The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70 (1996), 2318–2323.
32. [32] Haglund, K., Forman, J., Krausslich, H.G., Rose, J.K., Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology 268 (2000), 112–121.
33. [33] An, H.Y., Kim, G.N., Wu, K., Kang, C.Y., Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression. Virus Res 171 (2013), 168–177.
34. [34] Jeetendra, E., Ghosh, K., Odell, D., Li, J., Ghosh, H.P., Whitt, M.A., The membrane-proximal region of vesicular stomatitis virus glycoprotein G ectodomain is critical for fusion and virus infectivity. J Virol 77 (2003), 12807–12818.
35. [35] Jones, S.M., Feldmann, H., Stroher, U., Geisbert, J.B., Fernando, L., Grolla, A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11 (2005), 786–790.
36. [36] Marzi, A., Ebihara, H., Callison, J., Groseth, A., Williams, K.J., Geisbert, T.W., et al. Vesicular stomatitis virus-based Ebola vaccines with improved cross-protective efficacy. J Infect Dis 204:Suppl 3 (2011), S1066–S1074.
37. [37] Matassov, D., Marzi, A., Latham, T., Xu, R., Ota-Setlik, A., Feldmann, F., et al. Vaccination with a highly attenuated recombinant vesicular stomatitis virus vector protects against challenge with a lethal dose of Ebola virus. J Infect Dis, 2015.
38. [38] Falzarano, D., Geisbert, T.W., Feldmann, H., Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vacc 10 (2011), 63–77.
39. [39] Geisbert, T.W., Feldmann, H., Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 204:Suppl 3 (2011), S1075–S1081.
40. [40] Geisbert, T.W., Daddario-Dicaprio, K.M., Geisbert, J.B., Reed, D.S., Feldmann, F., Grolla, A., et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26 (2008), 6894–6900.
41. [41] Mire, C.E., Matassov, D., Geisbert, J.B., Latham, T.E., Agans, K.N., Xu, R., et al. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature 520 (2015), 688–691.
42. [42] Roberts, A., Buonocore, L., Price, R., Forman, J., Rose, J.K., Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73 (1999), 3723–3732.
43. [43] Mire, C.E., Miller, A.D., Carville, A., Westmoreland, S.V., Geisbert, J.B., Mansfield, K.G., et al. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis, 6, 2012, e1567.
44. [44] Geisbert, T.W., Daddario-Dicaprio, K.M., Lewis, M.G., Geisbert, J.B., Grolla, A., Leung, A., et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog, 4, 2008, e1000225.
45. [45] Whitt, M.A., Chong, L., Rose, J.K., Glycoprotein cytoplasmic domain sequences required for rescue of a vesicular stomatitis virus glycoprotein mutant. J Virol 63 (1989), 3569–3578.
46. [46] Clarke, D.K., Cooper, D., Egan, M.A., Hendry, R.M., Parks, C.L., Udem, S.A., Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol, 2006.
47. [47] Clarke, D.K., Nasar, F., Lee, M., Johnson, J.E., Wright, K., Calderon, P., et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations. J Virol 81 (2007), 2056–2064.
48. [48] Johnson, J.E., Nasar, F., Coleman, J.W., Price, R.E., Javadian, A., Draper, K., et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 360 (2007), 36–49.
49. [49] Clarke, D.K., Nasar, F., Chong, S., Johnson, J.E., Coleman, J.W., Lee, M., et al. Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates. J Virol 88 (2014), 6690–6701.
50. [50] Cooper, D., Wright, K.J., Calderon, P.C., Guo, M., Nasar, F., Johnson, J.E., et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 82 (2008), 207–219.
51. [51] Ahmed, M., McKenzie, M.O., Puckett, S., Hojnacki, M., Poliquin, L., Lyles, D.S., Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 77 (2003), 4646–4657.
52. [52] Gaddy, D.F., Lyles, D.S., Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol 79 (2005), 4170–4179.
53. [53] Stojdl, D.F., Lichty, B.D., tenOever, B.R., Paterson, J.M., Power, A.T., Knowles, S., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4 (2003), 263–275.
54. [54] U.S. Food and Drug Administration. 21 CFR 630 - Additional standards for viral vaccines, vol. 21. In: USFDA, editor; 1996.
55. [55] World Health Organization. Standard Operating Procedure: Neurovirulence test of types 1, 2 or 3 live poliomyelitis vaccines (oral) in monkeys; 2012.
56. [56] Yamanouchi, K., Uchida, N., Katow, S., Sato, T.A., Kobune, K., Growth of measles virus in nervous tissues. IV. Neurovirulence of wild measles and SSPE viruses in monkeys. Jpn J Med Sci Biol 29 (1976), 177–186.
57. [57] Levenbuk, I.S., Nikolayeva, M.A., Chigirinsky, A.E., Ralf, N.M., Kozlov, V.G., Vardanyan, N.V., et al. On the morphological evaluation of the neurovirulence safety of attenuated mumps virus strains in monkeys. J Biol Standard 7 (1979), 9–19.
58. [58] Levenbook, I.S., Pelleu, L.J., Elisberg, B.L., The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J Biol Standard 15 (1987), 305–313.
59. [59] Nathanson, N., Horn, S.D., Neurovirulence tests of type 3 oral poliovirus vaccine manufactured by Lederle Laboratories, 1964–1988. Vaccine 10 (1992), 469–474.
60. [60] Chen, R.T., Carbery, B., Mac, L., Berns, K.I., Chapman, L., Condit, R.C., et al. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Vaccine 33 (2015), 73–75.
61. [61] van den Broek, M.F., Muller, U., Huang, S., Zinkernagel, R.M., Aguet, M., Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev 148 (1995), 5–18.
62. [62] Tesh, R.B., Johnson, K.M., Hubbert, W.T., McCulloch, W.F., Schnurrenberger, P.R., Vesicular stomatitis. 1975, Charles C. Thomas, Springfield, Ill.
63. [63] Johnson, J.E., Coleman, J.W., Kalyan, N.K., Calderon, P., Wright, K.J., Obregon, J., et al. In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation. Vaccine 27 (2009), 2930–2939.
64. [64] Coil, D.A., Miller, A.D., Phosphatidylserine is not the cell surface receptor for vesicular stomatitis virus. J Virol 78 (2004), 10920–10926.
65. [65] Honke, N., Shaabani, N., Cadeddu, G., Sorg, U.R., Zhang, D.E., Trilling, M., et al. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol 13 (2012), 51–57.
66. [66] Finkelshtein, D., Werman, A., Novick, D., Barak, S., Rubinstein, M., LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci USA 110 (2013), 7306–7311.
67. [67] Barber, G.N., Vesicular stomatitis virus as an oncolytic vector. Viral Immunol 17 (2004), 516–527.
68. [68] Fultz, P.N., Shadduck, J.A., Kang, C.Y., Streilein, J.W., Vesicular stomatitis virus can establish persistent infections in Syrian hamsters. J Gen Virol 63 (1982), 493–497.
69. [69] Holland, J.J., Villarreal, L.P., Persistent noncytocidal vesicular stomatitis virus infections mediated by defective T particles that suppress virion transcriptase. Proc Natl Acad Sci USA 71 (1974), 2956–2960.
70. [70] Holland, J.J., Villarreal, L.P., Welsh, R.M., Oldstone, M.B., Kohne, D., Lazzarini, R., et al. Long-term persistent vesicular stomatitis virus and rabies virus infection of cells in vitro. J General Virol 33 (1976), 193–211.
71. [71] Tesh, R.B., Modi, G.B., Growth and transovarial transmission of Chandipura virus (Rhabdoviridae: Vesiculovirus) in phlebotomus papatasi. Am J Trop Med Hygiene 32 (1983), 621–623.
72. [72] Jonkers, A.H., The epizootiology of the vesicular stomatitis viruses: a reappraisal. Am J Epidemiol 86 (1967), 286–291.
73. [73] Mead, D.G., Ramberg, F.B., Besselsen, D.G., Mare, C.J., Transmission of vesicular stomatitis virus from infected to noninfected black flies co-feeding on nonviremic deer mice. Science 287 (2000), 485–487.
74. [74] Tesh, R.B., Peralta, P.H., Johnson, K.M., Ecologic studies of vesicular stomatitis virus. II. Results of experimental infection in Panamanian wild animals. Am J Epidemiol 91 (1970), 216–224.
75. [75] Tesh, R.B., Boshell, J., Modi, G.B., Morales, A., Young, D.G., Corredor, A., et al. Natural infection of humans, animals, and phlebotomine sand flies with the Alagoas serotype of vesicular stomatitis virus in Colombia. Am J Trop Med Hyg 36 (1987), 653–661.
76. [76] Fensterl, V., Wetzel, J.L., Ramachandran, S., Ogino, T., Stohlman, S.A., Bergmann, C.C., et al. Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog, 8, 2012, e1002712.
77. [77] Ciota, A.T., Kramer, L.D., Insights into arbovirus evolution and adaptation from experimental studies. Viruses 2 (2010), 2594–2617.
78. [78] Zimmer, B., Summermatter, K., Zimmer, G., Stability and inactivation of vesicular stomatitis virus, a prototype rhabdovirus. Vet Microbiol 162 (2013), 78–84.
79. [79] Mire, C.E., Geisbert, J.B., Versteeg, K.M., Mamaeva, N., Agans, K.N., Geisbert, T.W., et al. A single-vector, single-injection trivalent filovirus vaccine: proof of concept study in outbred guinea pigs. J Infect Dis 212:Suppl. 2 (2015), S384–S388.
80. [80] Rose, N.F., Roberts, A., Buonocore, L., Rose, J.K., Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 74 (2000), 10903–10910.
81. [81] Lawson, N.D., Stillman, E.A., Whitt, M.A., Rose, J.K., Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92 (1995), 4477–4481.
82. [82] Whelan, S.P., Ball, L.A., Barr, J.N., Wertz, G.T., Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci USA 92 (1995), 8388–8392.
83. [83] Ramsburg, E., Rose, N.F., Marx, P.A., Mefford, M., Nixon, D.F., Moretto, W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78 (2004), 3930–3940.
84. [84] Rose, N.F., Marx, P.A., Luckay, A., Nixon, D.F., Moretto, W.J., Donahoe, S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 (2001), 539–549.
85. [85] Kahn, J.S., Schnell, M.J., Buonocore, L., Rose, J.K., Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology 254 (1999), 81–91.
86. [86] Kahn, J.S., Roberts, A., Weibel, C., Buonocore, L., Rose, J.K., Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75 (2001), 11079–11087.
87. [87] Kapadia, S.U., Rose, J.K., Lamirande, E., Vogel, L., Subbarao, K., Roberts, A., Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340 (2005), 174–182.
88. [88] Reuter, J.D., Vivas-Gonzalez, B.E., Gomez, D., Wilson, J.H., Brandsma, J.L., Greenstone, H.L., et al. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 76 (2002), 8900–8909.
89. [89] Roberts, A., Kretzschmar, E., Perkins, A.S., Forman, J., Price, R., Buonocore, L., et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72 (1998), 4704–4711.
90. [90] Regules, J.A., Beigel, J.H., Paolino, K.M., Voell, J., Castellano, A.R., Munoz, P., et al. A recombinant vesicular stomatitis virus ebola vaccine - preliminary report. New Engl J Med, 2015.
91. [91] Huttner, A., Dayer, J.A., Yerly, S., Combescure, C., Auderset, F., Desmeules, J., et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis 15 (2015), 1156–1166.
92. [92] Agnandji, S.T., Huttner, A., Zinser, M.E., Njuguna, P., Dahlke, C., Fernandes, J.F., Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 374 (2016), 1647–1660.
93. [93] Ramsauer, K., Schwameis, M., Firbas, C., Mullner, M., Putnak, R.J., Thomas, S.J., et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis 15 (2015), 519–527.